Catalyst Dossier · compiled by CeliA 🧫

Eikon Therapeutics, Inc. (EIKN)

Biological Products, (No Diagnostic Substances) · market cap $520M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-10Earningsimp 5/10
2026-12-15 (est.)Phase 2 · Paclitaxelimp 7/10
2027-06-01 (est.)Phase 2 · IMP1734imp 7/10

Pipeline

Asset	Phase	Indication
EIK1004-001 (IMP1707-001)	Phase 2	Advanced Solid Tumors
IMP1734	Phase 2	Advanced Solid Tumor
EIK1005	Phase 2	Advanced Solid Tumors
EIK1001	Phase 3	Advanced Melanoma
Paclitaxel	Phase 2	NSCLC
BDB001	Phase 2	Tumor, Solid
Paclitaxel + Carboplatin	Phase 3	Non Small Cell Lung Cancer (Squamous or Non Squamous)

Price & technical context

3-month

+15.8%

6-month

—

12-month

—

52-wk range

$8.36–$16.26

vs 50-day MA

+19.3%

vs 200-day MA

—

Realized vol

94.6%

Max drawdown

-48.6%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for EIKN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.